News & Videos - GENEDRIVE ORD 1.5P

RiverFort is pleased to announce that it has arranged an Equity Prepayment Facility for up to £5 million (the "Facility") with Genedrive plc (LSE: GDR) (“Genedrive” or the “Company”), the point of care molecular diagnostics company, with an initial drawn amount of £2 million and committed capital advances of up to £3 million in 10 monthly instalments of £300,000 from 30 May 2023 which may be drawn down by the Company at its election. The Facility and the Company's existing cash...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult 05-Feb-2020 / 07:15 GMT/BST Hardman & Co Res earch : Western market progress but developing markets difficult Genedrive plc (GDR) is a commercial-stage biotech focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform offers low-cost, simple-to-use devices for highly sensitive and specific testing. The rapid analysis of samples aids...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay 21-Nov-2019 / 12:30 GMT/BST Hardman & Co Res earch : Regulatory hurdle leaped: hearing loss assay genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis of...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected 28-Oct-2019 / 07:30 GMT/BST Hardman & Co Res earch : Acceleration of news flow expected genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis of samples aids...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations 18-Jul-2019 / 07:30 GMT/BST Hardman & Co Research: Hepatitis C market frustrations genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis of infectious diseases. Rapid...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats 08-Apr-2019 / 10:53 GMT/BST Hardman & Co Research: First commercial sales in new focus area: bio-threats genedrive plc (GDR) is a commercial-stage company focused on point-of-care (PoC) molecular diagnostics. Its Genedrive(R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales 11-Dec-2018 / 07:15 GMT/BST Hardman & Co: Accelerating into fiscal 2019 with first sales genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis...

For release: 29 November genedrive plc ("genedrive" or the "Company") AbbVie sponsored REACH study for the use of Genedrive HCV assay in pharmacies genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that it will participate in an international multicentre trial (‘REACH’) to assess the impact of out-reach HCV diagnostics and therapy in a pharmacy setting versus conventional treatment pathways. The study, led by Prof. John Dillon, Professor of Hepatology...

For release: 2 October genedrive plc ("genedrive" or the "Company") genedrive to release Genedrive® Connect mobile app genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces phase 1 development of its Genedrive® connectivity solution, allowing for clinical data transmission from decentralised testing facilities. The new app is designed to enhance usability, but also provide functional surveillance-based data to further promote product adoption in the longer...

GENEDRIVE PARTNERS WITH FIND TO EVALUATE A MOLECULAR DIAGNOSTIC KIT FOR HEPATITIS C VIRUS IN DECENTRALISED SETTINGS Evaluation studies of the Genedrive® HCV ID Kit will take place in Cameroon and Georgia Assay designed for use in low-resource settings, delivering results in 90 minutes Manchester, U.K. and Geneva, Switzerland – 8 August 2018 – genedrive plc, a near patient molecular diagnostics company, and the Foundation for Innovation of New Diagnostics (FIND), announced today a study...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Preventing hearing loss in newborns 27-Jun-2018 / 07:15 GMT/BST Hardman & Co: Preventing hearing loss in newborns genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in infectious disease diagnosis. Rapid...

For release: 20 June 2018 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.  (“genedrive” or the “Company”) Grant to develop and implement a point-of-care test in the NHS to avoid antibiotic-related hearing loss...

Hardman & Co Hardman & Co Research: genedrive plc (GDR): Progressing commercialisation plans 12-Apr-2018 / 09:51 GMT/BST Hardman & Co Research: Progressing commercialisation plans Progressing commercialisation plans: genedrive plc (GDR) is a commercial-stage company focused on point-of-care/need molecular diagnostics and biomarkers. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity...

3 April 2018 genedrive plc ("genedrive" or the "Company") Genedrive® HCV ID Kit to be presented at MEDLAB Asia Pacific Exhibition & Congress genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces it will premiere its Genedrive® HCV ID Kit in the Asia Pacific region at the MEDLAB Asia Pacific Exhibition & Congress in Singapore on 2-4 April 2018. Genedrive® HCV ID Kit is a qualitative HCV assay, providing results within 90 minutes and is designed for use in a...

For release: 27 March The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. genedrive plc ("genedrive" or the "Company") genedrive signs distribution agreement for India with ARKRAY Healthcare pvt Ltd for Genedrive® HCV ID...

2 November 2017 genedrive plc ("genedrive" or the "Company") Update on Distribution arrangements for India / SAARC [1] genedrive plc (LSE:GDR), the molecular diagnostics company, today provides an update on its distribution arrangements in India / SAARC ("the Territory"). As previously announced, commercialisation of the MTB/RIF tuberculosis tests in India has been challenging for some time. Initially genedrive encountered a specific sample preparation problem which was subsequently identified...

genedrive plc ("genedrive" or the "Company") genedrive launches Genedrive® Hepatitis C test in Africa Genedrive® HCV ID Kit to be launched at IFCC WorldLab 2017 Congress genedrive plc (AIM: GDR), the near patient molecular diagnostics company, will launch the decentralised Hepatitis C assay, Genedrive® HCV ID Kit, at the IFCC WorldLab 2017 Congress from 22 - 25 October 2017 in Durban, South Africa. genedrive recently announced it had signed a distribution agreement with Sysmex Europe GmbH, a...

For release: 16 October 2017 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. genedrive plc ("genedrive" or the "Company") genedrive signs distribution agreement with Sysmex Europe GmbH("Sysmex Europe") Sysmex Europe to...

11 September 2017 genedrive plc ("genedrive" or the "Company") Genedrive® HCV ID Kit received CE-IVD Certification Hepatitis C assay provides decentralised molecular testing to support the identification of patients that could benefit from direct acting antiviral therapy genedrive plc (LSE:GDR), the molecular diagnostics company, today announces that the Company has achieved CE certification under the EU Medical Devices Directive for its Genedrive® HCV ID Kit, a qualitative molecular assay for...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......